3174 results for «310»
3174 results
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
Learn from the experts: lifetime management for Evolut first redo TAVI (TAV-in-TAV) and explant
14 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an in-depth exploration of lifetime management strategies for patients undergoing Evolut first redo TAVI procedures, including TAV-in-TAV and explant techniques. It provides a comprehensive understanding of clinical decision-making algorithms, technical challenges, and key considerations for successful procedural planning and execution, supported by real-world...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
SEISMIC-HF I - Exploring non-invasive methods for monitoring intracardiac filling pressures
16 Nov 2024
Luis Ortega provides his take on the SEISMIC-HF I study presented by Liviu Klein at AHA 2024, in Chicago.
Author
ECMO-CS – Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: primary results from the multicenter, randomized ECMO-CS trial
07 Nov 2022
Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation.
Author
The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events
01 Sep 2022
Alex Sticchi provides his take on the PRE18FFIR trial: Prediction of recurrent events with 18F-Sodium Fluoride to identify ruptured and high-risk coronary artery plaques in patients with myocardial infarction.
Author
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...
Author
Author
UNIVERSAL: routine ultrasonography guidance for femoral vascular access for cardiac procedures - A randomized clinical Trial
19 Sep 2022
Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
